Irina V. Sorokina
Irina V. Sorokina has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Anna M. Berezina
Russian Presidential Academy of National Economy and Public Administration
2 shared publications - Dar'JA A. Filonenko
Loginov Moscow Clinical Scientific Center
2 shared publications - Fedor B. Kryukov
JSC Biocad, Russian Federation
2 shared publications - Igor V. Samoylenko
Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of Russian Federation
2 shared publications - Inna P. Ganshina
Blokhin National Medical Research Center of Oncology
2 shared publications - Liudmila G. Zhukova
Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 21-29
Efficacy of neoadjuvant TCHP regimen with empegfilgrastim in early HER2-positive breast cancer: Final analysis of the DEFENDOR SPECIAL study, HER2+ BC cohort
Background. The DEFENDOR SPECIAL study (NCT04905329) evaluated the efficacy and safety of combination chemotherapy with empegfilgrastim for the primary prevention of neutropenia in patients with malignancies at high risk of recurrence. This article presents the results of an investigator-initiated analysis assessing the efficacy and safety of empegfilgrastim (Extimia®) in patients with stage II–III HER2-positive breast cancer (HER2+ BC) who received neoadjuvant therapy (NAT) with the TCHP regimen. Aim. To assess the clinical efficacy and safety of prolonged granulocyte colony-stimulating factor empegfilgrastim in patients with early HER2+ BCG treated with NAT as part of the TCHP regimen. Materials and methods. Data from 105 patients were analyzed. For the primary prevention of febrile neutropenia (FN), all patients received subcutaneous empegfilgrastim at a dose of 7.5 mg once per course. The primary endpoint was the relative dose intensity of the NAT courses, and the secondary endpoints included the complete pathomorphologic regression (pCR) rate, residual cancer burden (RCB), and adverse event rate. Comparison of pCR rates in this study and in the external control group of patients with early HER2+ BC of the clinical stage cT2-cT4/cN0-cN3/cM0, who received NAT in the TCHP regimen with filgrastim for the FN prevention from April 2020 to September 2023 at the Loginov Moscow Clinical Scientific Center. The matching based on the initial characteristics was performed using complete matching with the Mahalanobis distance. Results. In the DEFENDOR SPECIAL study, the median age (Q1–Q3) was 53 (43–61) years. The median relative dose intensity (Q1–Q3) was 97.1% (76.8–104.9%). PCR was achieved in 72.5% (76/105) of patients, while RCB-I and RCB-II were observed in 6.6% (7/105) and 15.2% (16/105), respectively. The highest pCR rate was observed in patients with HR-negative/HER2-positive (3+) tumors at 85.3% (29/34). No FN events were reported. Grade III–IV neutropenia occurred in 2.9% (3/105) of patients, grade I–II thrombocytopenia in 34.3% (36/105), and grade III thrombocytopenia in 1.0% (1/105). The probability of achieving pCR with empegfilgrastim was statistically significantly higher compared to filgrastim, with an adjusted odds ratio of 1.73 (95% confidence interval 1.04–2.89; p = 0.0357). Conclusion. Primary prevention of FN with empegfilgrastim offers a significant advantage in achieving pCR compared to filgrastim in patients with early HER2-positive breast cancer receiving a neoadjuvant TCHP regimen.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 21-29
Open AccessEfficacy of neoadjuvant TCHP regimen with empegfilgrastim in early HER2-positive breast cancer: Final analysis of the DEFENDOR SPECIAL study, HER2+ BC cohort
Background. The DEFENDOR SPECIAL study (NCT04905329) evaluated the efficacy and safety of combination chemotherapy with empegfilgrastim for the primary prevention of neutropenia in patients with malignancies at high risk of recurrence. This article presents the results of an investigator-initiated analysis assessing the efficacy and safety of empegfilgrastim (Extimia®) in patients with stage II–III HER2-positive breast cancer (HER2+ BC) who received neoadjuvant therapy (NAT) with the TCHP regimen. Aim. To assess the clinical efficacy and safety of prolonged granulocyte colony-stimulating factor empegfilgrastim in patients with early HER2+ BCG treated with NAT as part of the TCHP regimen. Materials and methods. Data from 105 patients were analyzed. For the primary prevention of febrile neutropenia (FN), all patients received subcutaneous empegfilgrastim at a dose of 7.5 mg once per course. The primary endpoint was the relative dose intensity of the NAT courses, and the secondary endpoints included the complete pathomorphologic regression (pCR) rate, residual cancer burden (RCB), and adverse event rate. Comparison of pCR rates in this study and in the external control group of patients with early HER2+ BC of the clinical stage cT2-cT4/cN0-cN3/cM0, who received NAT in the TCHP regimen with filgrastim for the FN prevention from April 2020 to September 2023 at the Loginov Moscow Clinical Scientific Center. The matching based on the initial characteristics was performed using complete matching with the Mahalanobis distance. Results. In the DEFENDOR SPECIAL study, the median age (Q1–Q3) was 53 (43–61) years. The median relative dose intensity (Q1–Q3) was 97.1% (76.8–104.9%). PCR was achieved in 72.5% (76/105) of patients, while RCB-I and RCB-II were observed in 6.6% (7/105) and 15.2% (16/105), respectively. The highest pCR rate was observed in patients with HR-negative/HER2-positive (3+) tumors at 85.3% (29/34). No FN events were reported. Grade III–IV neutropenia occurred in 2.9% (3/105) of patients, grade I–II thrombocytopenia in 34.3% (36/105), and grade III thrombocytopenia in 1.0% (1/105). The probability of achieving pCR with empegfilgrastim was statistically significantly higher compared to filgrastim, with an adjusted odds ratio of 1.73 (95% confidence interval 1.04–2.89; p = 0.0357). Conclusion. Primary prevention of FN with empegfilgrastim offers a significant advantage in achieving pCR compared to filgrastim in patients with early HER2-positive breast cancer receiving a neoadjuvant TCHP regimen.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 53-59
Long-acting G-CSF empegfilgrastim with dose-dense chemotherapy for patients with stage II–III TNBC: Defendor Special trial, primary analysis
Triple-negative breast cancer (TNBC) remains one of the most aggressive subtypes of breast cancer, associated with a high risk of early recurrence and limited systemic treatment options. Despite advances in neoadjuvant therapy, including platinum-based agents and immune checkpoint inhibitors, the widespread adoption of these approaches is limited by their toxicity, cost, and insufficient data on their combination with dose-dense regimens. Study objective. To evaluate the efficacy and safety of empegfilgrastim (a long-acting granulocyte colony-stimulating factor, G-CSF) in maintaining dose intensity during dose-dense neoadjuvant therapy (NAT) in patients with stage II–III triple-negative breast cancer (TNBC). Materials and methods. This prospective study enrolled 60 patients who received dose-dense chemotherapy with the ddAC regimen (doxorubicin + cyclophosphamide every 14 days) followed by weekly paclitaxel and carboplatin. Empegfilgrastim was administered once after each ddAC cycle. The primary endpoint was achieving a relative dose intensity (RDI) of ≥ 85 %. Results. The target RDI was achieved in 96 % of patients (median values: 100 % for ddAC and 94 % for weekly paclitaxel and carboplatin). Efficacy. A pathological complete response (pCR) was observed in 50 % of patients with localized (initially operable) disease and 43 % of those with locally advanced (initially inoperable) stages. Low residual tumor burden (RCB 0–1) was noted in 63 % of cases. Safety. The safety profile demonstrated a low incidence of severe adverse events (grade III–IV neutropenia: 1.7 %). Conclusion. Empegfilgrastim effectively maintains high dose intensity in NAT, leading to a significant pCR rate comparable to that of immunotherapy but with a more favorable safety profile.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 53-59
Long-acting G-CSF empegfilgrastim with dose-dense chemotherapy for patients with stage II–III TNBC: Defendor Special trial, primary analysis
Triple-negative breast cancer (TNBC) remains one of the most aggressive subtypes of breast cancer, associated with a high risk of early recurrence and limited systemic treatment options. Despite advances in neoadjuvant therapy, including platinum-based agents and immune checkpoint inhibitors, the widespread adoption of these approaches is limited by their toxicity, cost, and insufficient data on their combination with dose-dense regimens. Study objective. To evaluate the efficacy and safety of empegfilgrastim (a long-acting granulocyte colony-stimulating factor, G-CSF) in maintaining dose intensity during dose-dense neoadjuvant therapy (NAT) in patients with stage II–III triple-negative breast cancer (TNBC). Materials and methods. This prospective study enrolled 60 patients who received dose-dense chemotherapy with the ddAC regimen (doxorubicin + cyclophosphamide every 14 days) followed by weekly paclitaxel and carboplatin. Empegfilgrastim was administered once after each ddAC cycle. The primary endpoint was achieving a relative dose intensity (RDI) of ≥ 85 %. Results. The target RDI was achieved in 96 % of patients (median values: 100 % for ddAC and 94 % for weekly paclitaxel and carboplatin). Efficacy. A pathological complete response (pCR) was observed in 50 % of patients with localized (initially operable) disease and 43 % of those with locally advanced (initially inoperable) stages. Low residual tumor burden (RCB 0–1) was noted in 63 % of cases. Safety. The safety profile demonstrated a low incidence of severe adverse events (grade III–IV neutropenia: 1.7 %). Conclusion. Empegfilgrastim effectively maintains high dose intensity in NAT, leading to a significant pCR rate comparable to that of immunotherapy but with a more favorable safety profile.
- Open Access
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 378-384
The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
Aim. To assess the proportion and profile of patients at high risk of febrile neutropenia (FN) receiving cytotoxic chemotherapy (CT), as well as the incidence of FN and dose-limiting neutropenia after one cycle of CT. Materials and methods. The paper presents the results of the FLAME study, the first Russian observational study in patients with solid tumors who received only cytotoxic CT or a combination with targeted, immuno-oncological drugs. By random sampling, the study retrospectively included 500 patients with a median age of 59 years (18–83 years) from 25 medical institutions in the Russian Federation. Results. CT regimens with a high (20%) risk of FN were received by 25.2% (126/500) of patients; 53% (265/500) of patients had intermediate risk, and half of them (132/265 [49.8%]) had at least one additional risk FN factor following international NCCN guidelines. Thus, a high risk of FN, according to the therapy and the assessment of individual prognostic adverse factors, was noted in 51.6% (258/500) of patients. 36.8% (95/258) of patients with high risk for FN received primary prophylaxis with granulocyte colony-stimulating factors. Conclusion. The study showed a significant proportion of patients with a high risk of FN, and most of them do not receive primary prophylaxis of FN.
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 378-384
Open AccessThe frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
Aim. To assess the proportion and profile of patients at high risk of febrile neutropenia (FN) receiving cytotoxic chemotherapy (CT), as well as the incidence of FN and dose-limiting neutropenia after one cycle of CT. Materials and methods. The paper presents the results of the FLAME study, the first Russian observational study in patients with solid tumors who received only cytotoxic CT or a combination with targeted, immuno-oncological drugs. By random sampling, the study retrospectively included 500 patients with a median age of 59 years (18–83 years) from 25 medical institutions in the Russian Federation. Results. CT regimens with a high (20%) risk of FN were received by 25.2% (126/500) of patients; 53% (265/500) of patients had intermediate risk, and half of them (132/265 [49.8%]) had at least one additional risk FN factor following international NCCN guidelines. Thus, a high risk of FN, according to the therapy and the assessment of individual prognostic adverse factors, was noted in 51.6% (258/500) of patients. 36.8% (95/258) of patients with high risk for FN received primary prophylaxis with granulocyte colony-stimulating factors. Conclusion. The study showed a significant proportion of patients with a high risk of FN, and most of them do not receive primary prophylaxis of FN.
- Open Access
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 313-324
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination of PD-1 and CTLA-4 inhibitors a new standard of care for patients with metastatic melanoma (MM). A significant limitation of the widespread use of the combination of ipilimumab and nivolumab in routine clinical practice is the high risk of severe immune-mediated adverse events. Prolgolimab and nurulimab are a combination of fixed doses of original monoclonal antibodies (manufactured by JSC "BIOCAD," Russia) to the PD-1 receptor (prolgolimab) and the CTLA-4 receptor (nurulimab) (3:1 ratio). This paper presents the results of an international, multicenter, double-blind, placebo-controlled, comparative, randomized, phase II OBERTON clinical study to investigate the efficacy and safety of nurulimab + prolgolimab combination therapy with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable melanoma (uRM) or MM (NCT03913923). Materials and methods. The study included patients with uRM or MM who were not previously treated for metastatic disease. The patients were randomized into two groups (1:1). Patients in group 1 were treated with a nurulimab (1 mg/kg) and prolgolimab (3 mg/kg) combination at a dose of 0.2 mL/kg (equivalent to 1 mg/kg of nurulimab and 3 mg/kg of prolgolimab) once every 3 weeks during the first 4 blinded infusions. Patients in group 2 received prolgolimab monotherapy at a dose of 3 mg/kg once every 3 weeks during the first 4 blinded infusions. Starting from infusion 5, patients in both groups received open prolgolimab 1 mg/kg once every 2 weeks. The primary endpoint of the study was progression-free survival (PFS). The study is registered on ClinicalTrials.gov under the number NCT05732805 and is currently ongoing, but recruitment of new patients has been completed. Results. One hundred seventeen patients were randomized and received at least one dose of the study therapy. At a median follow-up of 16.79 months, the median PFS was 12.2 (4.9; not achieved) months in the nurulimab + prolgolimab group and 2.8 (1.5; 4.7) months in the prolgolimab monotherapy group (95% confidence interval 0.36-0.90, hazard ratio 0.57). PFS at 24 months was 41% in the nurulimab + prolgolimab group and 25.4% in the prolgolimab monotherapy group. In both groups, the therapy was well tolerated. Grade 3-4 immune-mediated adverse events were reported in 15.5% of patients who received nurulimab + prolgolimab, compared with 1.7% of those who received prolgolimab alone. The most frequent grade 3-4 treatment-related adverse events in both treatment groups were increased alanine aminotransferase and aspartate aminotransferase and asthenia. Overall, the safety profile was favorable, as expected for the class of immune checkpoint inhibitors, anti-CTLA-4, and anti-PD-1 monoclonal antibodies. Discussion. The results demonstrate a favorable safety profile in both the nurulimab + prolgolimab combination and prolgolimab monotherapy groups as the first-line treatment for uRM or MM. The assessment of the primary endpoint, PFS, showed the benefit of combination immunotherapy followed by switching to prolgolimab compared to prolgolimab alone. Conclusion. Combination immunotherapy with the CTLA-4 inhibitor nurulimab and the PD-1 inhibitor prolgolimab, available as a combination of solutions of two drugs in a single vial, with a further switch to monotherapy with prolgolimab, can fill an important niche in the treatment of patients with uRM or MM. Confirmation of the obtained data on the efficacy and safety of the combined regimen of nurulimab + prolgolimab in comparison with PD-1 inhibitor monotherapy is expected from the ongoing phase III BCD-217-2 OCTAVA study (NCT05732805).
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 313-324
Open AccessEfficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination of PD-1 and CTLA-4 inhibitors a new standard of care for patients with metastatic melanoma (MM). A significant limitation of the widespread use of the combination of ipilimumab and nivolumab in routine clinical practice is the high risk of severe immune-mediated adverse events. Prolgolimab and nurulimab are a combination of fixed doses of original monoclonal antibodies (manufactured by JSC "BIOCAD," Russia) to the PD-1 receptor (prolgolimab) and the CTLA-4 receptor (nurulimab) (3:1 ratio). This paper presents the results of an international, multicenter, double-blind, placebo-controlled, comparative, randomized, phase II OBERTON clinical study to investigate the efficacy and safety of nurulimab + prolgolimab combination therapy with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable melanoma (uRM) or MM (NCT03913923). Materials and methods. The study included patients with uRM or MM who were not previously treated for metastatic disease. The patients were randomized into two groups (1:1). Patients in group 1 were treated with a nurulimab (1 mg/kg) and prolgolimab (3 mg/kg) combination at a dose of 0.2 mL/kg (equivalent to 1 mg/kg of nurulimab and 3 mg/kg of prolgolimab) once every 3 weeks during the first 4 blinded infusions. Patients in group 2 received prolgolimab monotherapy at a dose of 3 mg/kg once every 3 weeks during the first 4 blinded infusions. Starting from infusion 5, patients in both groups received open prolgolimab 1 mg/kg once every 2 weeks. The primary endpoint of the study was progression-free survival (PFS). The study is registered on ClinicalTrials.gov under the number NCT05732805 and is currently ongoing, but recruitment of new patients has been completed. Results. One hundred seventeen patients were randomized and received at least one dose of the study therapy. At a median follow-up of 16.79 months, the median PFS was 12.2 (4.9; not achieved) months in the nurulimab + prolgolimab group and 2.8 (1.5; 4.7) months in the prolgolimab monotherapy group (95% confidence interval 0.36-0.90, hazard ratio 0.57). PFS at 24 months was 41% in the nurulimab + prolgolimab group and 25.4% in the prolgolimab monotherapy group. In both groups, the therapy was well tolerated. Grade 3-4 immune-mediated adverse events were reported in 15.5% of patients who received nurulimab + prolgolimab, compared with 1.7% of those who received prolgolimab alone. The most frequent grade 3-4 treatment-related adverse events in both treatment groups were increased alanine aminotransferase and aspartate aminotransferase and asthenia. Overall, the safety profile was favorable, as expected for the class of immune checkpoint inhibitors, anti-CTLA-4, and anti-PD-1 monoclonal antibodies. Discussion. The results demonstrate a favorable safety profile in both the nurulimab + prolgolimab combination and prolgolimab monotherapy groups as the first-line treatment for uRM or MM. The assessment of the primary endpoint, PFS, showed the benefit of combination immunotherapy followed by switching to prolgolimab compared to prolgolimab alone. Conclusion. Combination immunotherapy with the CTLA-4 inhibitor nurulimab and the PD-1 inhibitor prolgolimab, available as a combination of solutions of two drugs in a single vial, with a further switch to monotherapy with prolgolimab, can fill an important niche in the treatment of patients with uRM or MM. Confirmation of the obtained data on the efficacy and safety of the combined regimen of nurulimab + prolgolimab in comparison with PD-1 inhibitor monotherapy is expected from the ongoing phase III BCD-217-2 OCTAVA study (NCT05732805).
- Open Access
- 17 May 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (1) , 115-122
Prevention of febrile neutropenia in oncological patients: real-world data
Aim. To assess the effect of febrile neutropenia (FN) prophylaxis with granulocyte colony-stimulating factors (G-CSF) in real-world cancer patients. Materials and methods. We conducted a statistical analysis of anonymized medical records collected in the Webiomed platform. Before analysis, the cards were validated by clinical experts. Electronic records were extracted according to two principles: mentioning D70 in the diagnosis or mentioning a chemotherapy regimen associated with a high risk of FN (20%), requiring the primary prevention of neutropenia. Thus, we obtained two datasets comprising 47.085 (590 patients) and 30.523 (398 patients) records, respectively. Results. Based on the analysis results, the most common risk factors for FN development were highly hematologically toxic chemotherapy regimens and elderly age about 50% in the adult population. In both datasets, the number of female patients prevailed (63.7% in dataset 1, 91.2% in dataset 2), so the most common was breast cancer. Less common were cervical cancer, digestive cancer, and lung cancer. Despite the indications for primary prevention of FN, for safety and importance of achieving the planned dose intensity, it was administered in 18.3% of patients in dataset 1 and 2.3% in dataset 2. No FN or G-CSF-related adverse events were reported in patients who received adequate primary prevention. Conclusion. Some issues related to G-CSF administration in cancer patients were identified. We identified the insufficient provision of patients with primary prevention of FN, which negatively affects survival rates and reduces adherence to antitumor therapy. Real-world data demonstrate the efficacy and safety of FN prevention and planned dose intensity maintance in cytotoxic therapy regimens.
- 17 May 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (1) , 115-122
Open AccessPrevention of febrile neutropenia in oncological patients: real-world data
Aim. To assess the effect of febrile neutropenia (FN) prophylaxis with granulocyte colony-stimulating factors (G-CSF) in real-world cancer patients. Materials and methods. We conducted a statistical analysis of anonymized medical records collected in the Webiomed platform. Before analysis, the cards were validated by clinical experts. Electronic records were extracted according to two principles: mentioning D70 in the diagnosis or mentioning a chemotherapy regimen associated with a high risk of FN (20%), requiring the primary prevention of neutropenia. Thus, we obtained two datasets comprising 47.085 (590 patients) and 30.523 (398 patients) records, respectively. Results. Based on the analysis results, the most common risk factors for FN development were highly hematologically toxic chemotherapy regimens and elderly age about 50% in the adult population. In both datasets, the number of female patients prevailed (63.7% in dataset 1, 91.2% in dataset 2), so the most common was breast cancer. Less common were cervical cancer, digestive cancer, and lung cancer. Despite the indications for primary prevention of FN, for safety and importance of achieving the planned dose intensity, it was administered in 18.3% of patients in dataset 1 and 2.3% in dataset 2. No FN or G-CSF-related adverse events were reported in patients who received adequate primary prevention. Conclusion. Some issues related to G-CSF administration in cancer patients were identified. We identified the insufficient provision of patients with primary prevention of FN, which negatively affects survival rates and reduces adherence to antitumor therapy. Real-world data demonstrate the efficacy and safety of FN prevention and planned dose intensity maintance in cytotoxic therapy regimens.